Multiple Myeloma / IMS 10/09/2026

Part 2: Key Considerations for Bridging Therapy Before CAR T-Cell Infusion

Key Points

  • Early CAR T-cell evaluation is critical in ensuring that bridging therapy does not compromise T-cell collection or subsequent treatment efficacy.
  • BCMA-directed therapies and bispecific antibodies should generally be avoided before apheresis due to concerns about T-cell fitness and CAR T-cell manufacturing.
  • Bridging therapy should be tailored to disease kinetics, with alternative approaches considered for patients with rapidly progressive disease who may not be able to safely wait for CAR T-cell manufacturing.

For patients with multiple myeloma, bridging therapy can provide critical disease control while they await CAR T-cell manufacturing and infusion. Treatment selection, however, should begin with early evaluation at a CAR T-cell center. In the second part of a discussion on CAR T-Cell therapy, Hamza Hashmi, MD, of Memorial Sloan Kettering Cancer Center, and Ajai Chari, MD, of UCSF Health, review practical factors such as the patient’s ability to travel, caregiver availability, time away from work, and willingness to accept potential treatment-related toxicities. The interview coincided with the 2026 International Myeloma Society (IMS) meeting, held in Glasgow, Scotland, from September 23–26.

Optimizing Bridging Therapy Before CAR T-Cell Therapy

In this patient group, the choice of therapy prior to apheresis requires particular attention. BCMA-directed therapies should generally be avoided before the patient has been evaluated and collected for CAR T-cell therapy, given concerns that prior BCMA exposure may adversely affect subsequent BCMA-directed treatment, Dr. Chari said. Bispecific antibodies should similarly be avoided before apheresis when possible, due to concerns around T-cell exhaustion and its potential impact on collection.

Once apheresis is complete, the range of bridging options expands. Therapies such as talquetamab that target a different antigen can help control disease while the CAR T-cell product is manufactured. Other agents should also be considered based on the patient’s prior treatment history and disease characteristics. The discussion highlighted the potential role of newer agents, including CELMoDs, to provide disease control while potentially supporting T-cell function.

Disease kinetics should ultimately guide the urgency and intensity of bridging therapy, the doctors noted. Patients with relatively indolent or biochemical relapse may be able to maintain adequate disease control by adding agents to an existing regimen while navigating the manufacturing process. In contrast, patients with rapidly progressive or explosive disease may not have sufficient time to safely proceed to CAR T-cell infusion and may be better served by an alternative treatment, including a bispecific antibody. In these cases, controlling the disease may take priority over pursuing CAR T-cell therapy.

With CAR T-cell therapy now available earlier in the multiple myeloma treatment course, clinicians have more options for controlling disease while preserving the opportunity for cellular therapy. Early referral allows clinicians to sequence treatment around apheresis and avoid potentially detrimental therapies before collection.